• Development of a new degradable ionizable lipid, AMG1541, for mRNA vaccines that significantly enhances potency and enables similar protective immunity at 100-fold lower doses than current standards, while also reducing toxicity and improving clearance in vivo
• Enhanced protein expression in antigen presenting cells and enhanced germinal center reactions giving rise to antigen specific B cells
• Detailed structure-activity relationship studies to unravel mechanistic aspects

NEW DATA

NEW COMPANY